233 related articles for article (PubMed ID: 21855111)
21. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma.
Davidson B; Shih IeM; Wang TL
Hum Pathol; 2008 Nov; 39(11):1630-6. PubMed ID: 18656238
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
23. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
[TBL] [Abstract][Full Text] [Related]
24. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.
Kleinberg L; Dong HP; Holth A; Risberg B; Trope' CG; Nesland JM; Flørenes VA; Davidson B
Hum Pathol; 2009 Jun; 40(6):795-806. PubMed ID: 19157506
[TBL] [Abstract][Full Text] [Related]
25. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
Vaksman O; Davidson B; Tropé C; Reich R
Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
[TBL] [Abstract][Full Text] [Related]
26. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.
Davidson B; Rosenfeld YB; Holth A; Hellesylt E; Tropé CG; Reich R; Yisraeli JK
Hum Pathol; 2014 Jul; 45(7):1520-8. PubMed ID: 24814803
[TBL] [Abstract][Full Text] [Related]
27. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
[TBL] [Abstract][Full Text] [Related]
28. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
[TBL] [Abstract][Full Text] [Related]
29. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.
Tuft Stavnes H; Nymoen DA; Hetland Falkenthal TE; Kærn J; Tropé CG; Davidson B
Am J Clin Pathol; 2014 Jul; 142(1):51-7. PubMed ID: 24926085
[TBL] [Abstract][Full Text] [Related]
30. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K; Nymoen DA; Reich R; Davidson B
Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
[TBL] [Abstract][Full Text] [Related]
31. Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
Yuan Y; Nymoen DA; Stavnes HT; Rosnes AK; Bjørang O; Wu C; Nesland JM; Davidson B
Am J Surg Pathol; 2009 Nov; 33(11):1673-82. PubMed ID: 19738457
[TBL] [Abstract][Full Text] [Related]
32. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
[TBL] [Abstract][Full Text] [Related]
33. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
[TBL] [Abstract][Full Text] [Related]
34. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R
Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420
[TBL] [Abstract][Full Text] [Related]
35. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
37. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
38. PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.
Yuan Y; Dong HP; Nymoen DA; Nesland JM; Wu C; Davidson B
Cytopathology; 2011 Feb; 22(1):22-9. PubMed ID: 20500520
[TBL] [Abstract][Full Text] [Related]
39. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.
Bock AJ; Tuft Stavnes H; Kærn J; Berner A; Staff AC; Davidson B
Tumour Biol; 2011 Jun; 32(3):589-96. PubMed ID: 21350924
[TBL] [Abstract][Full Text] [Related]
40. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
